Low-dose temozolomide selectively increases glioblastoma's vascular permeability, tumor microenvironment penetration and the killing potential of systemic actinium-225 α-particle dendrimer-radioconjugates improving treatment efficacy.

Nair RR, Sarkar A, Hariharan P, Gabrielson KL, Wu T, Liu C, Sharma A, Liyanage W, Bhujwalla ZM, Vidaver MP, Kannan RM, Sofou S

Open source

DOI: 10.1007/s00259-025-07332-w
Published: 2025 Sep
Container: European journal of nuclear medicine and molecular imaging
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00259-025-07332-w,
  title = {Low-dose temozolomide selectively increases glioblastoma's vascular permeability, tumor microenvironment penetration and the killing potential of systemic actinium-225 α-particle dendrimer-radioconjugates improving treatment efficacy.},
  author = {Nair RR and Sarkar A and Hariharan P and Gabrielson KL and Wu T and Liu C and Sharma A and Liyanage W and Bhujwalla ZM and Vidaver MP and Kannan RM and Sofou S},
  year = {2025},
  journal = {European journal of nuclear medicine and molecular imaging},
  doi = {10.1007/s00259-025-07332-w},
  url = {https://doi.org/10.1007/s00259-025-07332-w}
}

RIS

TY  - JOUR
TI  - Low-dose temozolomide selectively increases glioblastoma's vascular permeability, tumor microenvironment penetration and the killing potential of systemic actinium-225 α-particle dendrimer-radioconjugates improving treatment efficacy.
AU  - Nair RR
AU  - Sarkar A
AU  - Hariharan P
AU  - Gabrielson KL
AU  - Wu T
AU  - Liu C
AU  - Sharma A
AU  - Liyanage W
AU  - Bhujwalla ZM
AU  - Vidaver MP
AU  - Kannan RM
AU  - Sofou S
PY  - 2025
JO  - European journal of nuclear medicine and molecular imaging
DO  - 10.1007/s00259-025-07332-w
UR  - https://doi.org/10.1007/s00259-025-07332-w
ER  -

APA

RR, N., A, S., P, H., KL, G., T, W., C, L., A, S., W, L., ZM, B., MP, V., RM, K., & S, S. (2025). Low-dose temozolomide selectively increases glioblastoma's vascular permeability, tumor microenvironment penetration and the killing potential of systemic actinium-225 α-particle dendrimer-radioconjugates improving treatment efficacy.. European journal of nuclear medicine and molecular imaging. https://doi.org/10.1007/s00259-025-07332-w

Source records

pubmed · retrieved 2026-09-26T00:32:36.669Z